Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer
Evaxion Biotech A/S - American Depositary Share (EVAX)
Company Research
Source: GlobeNewswire
Dr Tayton-Martin brings broad experience of biotech company building, fund-raising, M&A, business development and operations with a strong track record of strategic partnership dealsHer more than 30 years of experience include leadership roles in the UK and US, from early research through to product approval in cancer immunotherapy, making her the ideal candidate to lead the next stage of execution of Evaxion’s strategy Birgitte Rønø, who has served as interim Chief Executive Officer, will continue in her role as Chief Scientific OfficerSeasoned life science executive Jens Bitsch-Norhave will join as observer and advisor to the Board of Directors with the intention of seeking election at the next Annual General Meeting COPENHAGEN, Denmark, October 27, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has appointed Dr Helen Tayton-Martin as new Chief Executive Officer (CEO). She will take up her
Show less
Read more
Impact Snapshot
Event Time:
EVAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EVAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EVAX alerts
High impacting Evaxion Biotech A/S - American Depositary Share news events
Weekly update
A roundup of the hottest topics
EVAX
News
- Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1GlobeNewswire
- Evaxion announce 2026 financial calendarGlobeNewswire
- Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 [Yahoo! Finance]Yahoo! Finance
- Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01GlobeNewswire
- Evaxion announces business update and third quarter 2025 financial resultsGlobeNewswire
EVAX
Sec Filings
- 11/21/25 - Form F-1
- 11/20/25 - Form 6-K
- 11/18/25 - Form 6-K
- EVAX's page on the SEC website